Saturday, 16 JUNE 2018 2018
DOI: 10.1136/annrheumdis-2018-eular.3026
|View full text |Cite
|
Sign up to set email alerts
|

SAT0360 A summary of clinical evidence for commonly used uricosurics for gout in europe

Abstract: BackgroundUricosurics (benzbromarone, probenecid, or sulfinpyrazone) are recommended for second-line treatment of gout if treatment target cannot be achieved with allopurinol or if allopurinol cannot be tolerated. While some uricosurics have been available since the 1970s, only two head-to-head trials have been conducted, both of which compared benzbromarone with probenecid. A new uricosuric, lesinurad, has recently been developed, but also has no head-to-head data against current uricosurics. There is therefo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2019
2019

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…Until now, uricosurics have never gone through extensive clinical trials 12. We have no data on long-term safety for other medications, although there is empirical evidence based only on expertise.…”
Section: Discussionmentioning
confidence: 99%
“…Until now, uricosurics have never gone through extensive clinical trials 12. We have no data on long-term safety for other medications, although there is empirical evidence based only on expertise.…”
Section: Discussionmentioning
confidence: 99%